Deal sells common shares at $7.00 apiece with $6.51 million greenshoe
By Devika Patel
Knoxville, Tenn., Nov. 15 - NewLink Genetics Corp. priced its $43.4 million initial public offering of stock with a $6.51 million greenshoe in a prospectus filed Thursday with the Securities and Exchange Commission. It expects the shares to trade on the Nasdaq under the symbol "NLNK."
The company will sell 6.2 million common shares at $7.00 per share. Stine Seed Farm, Inc. will invest $15 million.
The deal is being conducted by joint bookrunning managers Stifel, Nicolaus & Co., Inc., Canaccord Genuity Inc., Robert W. Baird & Co. Inc. and Cantor Fitzgerald & Co.
Settlement is expected Nov. 16.
Proceeds will be used for clinical trials, research and development activities for product candidates, working capital and other general corporate purposes.
The biopharmaceutical company is based in Ames, Iowa.
| Issuer: | NewLink Genetics Corp.
|
| Issue: | Common stock
|
| Amount: | $43.4 million
|
| Greenshoe: | $6.51 million
|
| Shares: | 6.2 million
|
| Price: | $7.00
|
| Warrants: | No
|
| Bookrunners: | Stifel, Nicolaus & Co., Inc., Canaccord Genuity Inc., Robert W. Baird & Co. Inc. and Cantor Fitzgerald & Co.
|
| Investors: | Stine Seed Farm, Inc. (for $15 million)
|
| Pricing date: | Nov. 10
|
| Settlement date: | Nov. 16
|
| Stock exchange: | Nasdaq: NLNK
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
